The modern therapeutic & imaging landscape of metastatic prostate cancer: a primer for radiologists

Abdom Radiol (NY). 2022 Feb;47(2):781-800. doi: 10.1007/s00261-021-03348-6. Epub 2021 Nov 16.

Abstract

Prostate cancer represents one of the leading causes of cancer-related mortality in the United States and the most common cancer among men. Treatment paradigms for the management of advanced stages of prostate cancer have continued to evolve in recent years. These advancements in the therapeutic landscape of metastatic prostate cancer and diagnostic imaging modalities have fundamentally changed the treatment of patients with prostate cancer. In this review article we provide a primer for radiologists highlighting the most recent developments in treatment options and imaging techniques utilized in the modern oncologic management of metastatic prostate cancer. We will examine current therapy options and associated toxicities with an emphasis on relevant imaging findings commonly encountered by radiologists. We also summarize the role of modalities including CT, MRI, PET, bone scintigraphy, and PET in the diagnosis and follow-up of patients with metastatic prostate cancer.

Keywords: Drug toxicity; Immunotherapy; Metastatic disease; Oncologic imaging; Prostate cancer; Targeted therapy.

Publication types

  • Review

MeSH terms

  • Humans
  • Magnetic Resonance Imaging
  • Male
  • Prostatic Neoplasms* / diagnostic imaging
  • Prostatic Neoplasms* / therapy
  • Radiologists